Associations between age, cytogenetics, FLT3-ITD, and marrow leukemia cells identified by flow cytometry

Asian Pacific Journal of Cancer Prevention

Volumn 14, Issue 9, 2013, Pages 5341-5344

  Su, Long ^a   Gao, Su Jun ^a   Tan, Ye Hui ^a   Han, Wei ^a   Li, Wei ^a  

^a JILIN UNIVERSITY   (China)

Author keywords

Acute myeloid leukemia; Age; Cytogenetics; Leukemia cells; Molecular mutations

Indexed keywords

CCAAT ENHANCER BINDING PROTEIN; CD135 ANTIGEN; CEBPA PROTEIN, HUMAN; FLT3 PROTEIN, HUMAN; NUCLEAR PROTEIN; NUCLEOPHOSMIN;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ARTICLE; BONE MARROW; CHILD; CHROMOSOME ANALYSIS; FEMALE; FLOW CYTOMETRY; GENETICS; HUMAN; IMMUNOPHENOTYPING; MALE; MIDDLE AGED; MUTATION; PATHOLOGY; PROGNOSIS; SENSITIVITY AND SPECIFICITY; TANDEM REPEAT; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BONE MARROW; CCAAT-ENHANCER-BINDING PROTEINS; CHILD; CYTOGENETIC ANALYSIS; FEMALE; FLOW CYTOMETRY; FMS-LIKE TYROSINE KINASE 3; HUMANS; IMMUNOPHENOTYPING; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; MUTATION; NUCLEAR PROTEINS; PROGNOSIS; SENSITIVITY AND SPECIFICITY; TANDEM REPEAT SEQUENCES; YOUNG ADULT;

EID: 84887571335     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2013.14.9.5341     Document Type: Article

References (23)

1. Appelbaum FR, Gundacker H, Head DR, et al (2006). Age and acute myeloid leukemia. Blood, 107, 3481-5.
2. Gardini A, Cesaroni M, Luzi L, et al (2008). AML1/ETO oncoprotein is directed to AML1 binding regions and colocalizes with AML1 and HEB on its tar gets. PloS Genet, 4, e1000275.
3. Gilliland DG, Grifn JD (2002). Role of FLT3 in leukemia. Curr Opin Hematol, 9, 274-81.
4. Grisolano JL, Wesselschmidt RL, Pelicci PG, et al (1997). Altered myeloid development and acute leukemia in transgenic mice expressing PML-RAR under control of cathepsin G regulatory sequences. Blood, 89, 376-87.
5. Haferlach T, Bacher U, Alpermann T, et al (2012). Amount of bone marrow blasts is strongly correlated to NPM1 and FLT3-ITD mutation rate in AML with normal karyotype. Leuk Res, 36, 51-8.
6. Hayakawa F, Towatari M, Kiyoi H, et al (2000). Tandem-duplicated Flt3 constitutively activates STAT5 and MAP kinase and introduces autonomous cell growth in IL-3-dependent cell lines. Oncogene, 19, 624-31.
7. Hollink IH, Zwaan CM, Zimmermann M, et al (2009). Favorable prognostic impact of NPM1 gene mutations in childhood acute myeloid leukemia, with emphasis on cytogenetically normal AML. Leukemia, 23, 262-70.
8. ISCN (2009). An international system for human cytogenetic nomenclature. Shaffer LG, Slovak ML, Campbell LJ, eds. S. Krager; Basel.
9. Kaleem Z, Crawford E, Pathan MH, et al (2003). Flow cytometric analysis of acute leukemias. Diagnostic utility and critical analysis of data. Arch Pathol Lab Med, 127, 42-8.
10. Kelly LM, Liu Q, Kutok JL, et al (2002). FLT3 internal tandem duplication mutations associated with human acute myeloid leukemias induce myeloproliferative disease in a murine bone marrow transplant model. Blood, 99, 310-18.
11. Li Y, Gao L, Luo X, et al (2013). Epigenetic silencing of microRNA-193a contributes to leukemogenesis in t(8;21) acute myeloid leukemia by activating the PTEN/PI3K signal pathway. Blood, 121, 499-509.
12. Mizuki M, Fenski R, Halfter H, et al (2000). Flt3 mutations from patients with acute myeloid leukemia induce transformation of 32D cells mediated by the RAS and STAT5 pathway. Blood, 96, 3907-14.
13. Park SH, Chi HS, Min SK, et al (2011). Prognostic impact of c-KIT mutations in core binding factor acute myeloid leukemia. Leuk Res, 35, 1376-83.
14. Puccetti E, Ruthardt M (2004). Acute promyelocytic leukemia: PML/RARa and the leukemia stem cell. Leukemia, 18, 1169-75.
15. Rajaraman R, Guernsey DL, Rajaraman MM, et al (2006). Stem cells, senescence, neosis and self-renewal in cancer. Cancer Cell Int, 6, 25.
16. Schneider F, Hoster E, Schneider S, et al (2012). Age-dependent frequencies of NPM1 mutations and FLT3-ITD in patients with normal karyotype AML (NK-AML). Ann Hematol, 91, 9-18.
17. Schnittger S, Schoch C, Dugas M, et al (2002). Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease. Blood, 100, 59-66.
18. Schnittger S, Schoch C, Kern W, et al (2005). Nucleophosmin gene mutations are predictors of favorable prognosis in acute myelogenous leukemia with a normal karyotype. Blood, 106, 3733-9.
19. Steffen B, Knop M, Bergholz U, et al (2011). AML1/ETO induces self-renewal in hematopoietic progenitor cells via the Groucho-related amino-terminal AES protein. Blood, 117, 4328-37.
20. Su L, Gao S, Li W, et al (2013). Age-specific distributions of cytogenetic subgroups of acute myeloid leukemia: data analysis in a Chinese population. Acta Haematol, 129, 175-81.
21. Thiede C, Steudel C, Mohr B, et al (2002). Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis. Blood, 99, 4326-35.
22. Wang YY, Zhao LJ, Wu CF, et al (2011). C-KIT mutation cooperates with full-length AML1-ETO to induce acute myeloid leukemia in mice. Proc Natl Acad Sci USA, 108, 2450-5.
23. Wouters BJ, Löwenberg B, Erpelinck-Verschueren CA, et al (2009). Double CEBPA mutations, but not single CEBPA mutations, define a subgroup of acute myeloid leukemia with a distinctive gene expression profile that is uniquely associated with a favorable outcome. Blood, 113, 3088-91.